1.37 USD
-0.09 (-6.16%)
Last: Jan 30, 2026, 08:00 PM
ENTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ENTX as it has an excellent financial health rating, but there are worries on the profitability. ENTX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past year ENTX has reported negative net income.
- In the past year ENTX has reported a negative cash flow from operations.
- In the past 5 years ENTX always reported negative net income.
- In the past 5 years ENTX always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -61.93%, ENTX perfoms like the industry average, outperforming 41.33% of the companies in the same industry.
- ENTX has a Return On Equity (-70.77%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -61.93% | ||
| ROE | -70.77% | ||
| ROIC | N/A |
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- ENTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- ENTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, ENTX has more shares outstanding
- Compared to 5 years ago, ENTX has more shares outstanding
- There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
- ENTX has an Altman-Z score of 6.53. This indicates that ENTX is financially healthy and has little risk of bankruptcy at the moment.
- ENTX has a Altman-Z score of 6.53. This is in the better half of the industry: ENTX outperforms 78.29% of its industry peers.
- ENTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 6.53 |
ROIC/WACCN/A
WACC8.73%
2.3 Liquidity
- ENTX has a Current Ratio of 10.83. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
- ENTX has a Current ratio of 10.83. This is amongst the best in the industry. ENTX outperforms 85.14% of its industry peers.
- ENTX has a Quick Ratio of 10.83. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 10.83, ENTX belongs to the top of the industry, outperforming 85.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.83 | ||
| Quick Ratio | 10.83 |
3. Growth
3.1 Past
- ENTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.00%, which is quite impressive.
- ENTX shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.49% yearly.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%-100%
3.2 Future
- Based on estimates for the next years, ENTX will show a very negative growth in Earnings Per Share. The EPS will decrease by -66.57% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.24%
EPS Next 2Y-66.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-69.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for ENTX. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ENTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- ENTX's earnings are expected to decrease with -66.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-66.57%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for ENTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
ENTERA BIO LTD / ENTX FAQ
What is the fundamental rating for ENTX stock?
ChartMill assigns a fundamental rating of 3 / 10 to ENTX.
Can you provide the valuation status for ENTERA BIO LTD?
ChartMill assigns a valuation rating of 0 / 10 to ENTERA BIO LTD (ENTX). This can be considered as Overvalued.
How profitable is ENTERA BIO LTD (ENTX) stock?
ENTERA BIO LTD (ENTX) has a profitability rating of 1 / 10.
What is the earnings growth outlook for ENTERA BIO LTD?
The Earnings per Share (EPS) of ENTERA BIO LTD (ENTX) is expected to decline by -14.24% in the next year.